Diabetes Devices Market (2026 - 2033) Size, Share & Trends Analysis Report By Type (BGM Devices, Insulin Delivery), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/ Centers, Online Pharmacies), By End-use, By Region, And Segment Forecasts

Diabetes Devices Market Summary

The global diabetes devices market sizewas estimated at USD 45.85 billion in 2025 and is projected to reach USD 101.66 billion by 2033, growing at a CAGR of 10.5% from 2026 to 2033. The market is primarily driven by growing prevalence of diabetes, advanced technology, the growing usage of insulin delivery devices, and the rise in obesity rates.

Major manufacturers are concentrating on technological innovation and the creation of advanced products to secure a significant portion of the diabetes care devices market. For instance, in January 2025, Dexcom announced the expansion of its AI-enabled continuous glucose monitoring ecosystem through new integrations with digital health and automated insulin delivery platforms to improve personalized diabetes management and remote patient monitoring capabilities. The development strengthened the company’s connected diabetes care portfolio and is expected to accelerate the adoption of advanced CGM and automated insulin delivery technologies globally, thereby supporting the diabetes management devices market growth.

The increasing prevalence of diabetes worldwide has created a strong demand for diabetes devices over the forecast period. According to the latest 11th Edition of the International Diabetes Federation (IDF) Diabetes Atlas published in 2025, approximately 589 million adults aged 20-79 years are currently living with diabetes globally, representing nearly 1 in 9 adults worldwide. The organization further projects that the number of adults living with diabetes likely to increase to nearly 853 million by 2050, reflecting the rapidly growing global disease burden. In addition, more than 40% of diabetic individuals remain undiagnosed, increasing the risk of severe complications and driving the need for continuous glucose monitoring systems, insulin delivery devices, and early diagnostic technologies. Furthermore, over 81% of people with diabetes live in low- and middle-income countries, highlighting significant growth opportunities for affordable and connected diabetes care solutions across emerging markets. These rising prevalence trends, coupled with increasing obesity rates, sedentary lifestyles, and aging populations, are expected to significantly support the growth of the diabetes devices market during the forecast period.

The increasing demand in the diabetes care drugs devices market is largely driven by the growing need to reduce diabetes-related complications, prevent prolonged hospital stays, and lower mortality rates among diabetic patients. Diabetes devices such as continuous glucose monitors, insulin delivery systems, and blood glucose monitoring devices enable real-time tracking and effective management of blood sugar levels, helping patients take timely action to control their condition. These technologies support better treatment adherence and allow healthcare providers to make faster adjustments to therapy plans, resulting in improved disease management and patient outcomes. In addition, the rising adoption of advanced diabetes care solutions is improving the overall quality of life for individuals living with diabetes by minimizing the risk of severe health complications. Consequently, the expanding use of these devices continues to strengthen the growth of the diabetes care drugs devices market by enhancing patient care, improving clinical efficiency, and supporting long-term disease management.

The market is growing due to the increasing prevalence of diabetes resulting from aging, obesity, and unhealthy lifestyle choices. Obesity is a significant factor leading to diabetes. According to the latest data published by the World Health Organization in 2025, more than 2.5 billion adults aged 18 years and older were overweight in 2022, including over 890 million adults living with obesity. In addition, the worldwide prevalence of obesity has more than doubled since 1990, with approximately 16% of the global adult population classified as obese. Furthermore, the World Obesity Federation reported in its 2025 World Obesity Atlas that the number of adults living with obesity is projected to increase nearly 1.53 billion by 2035. Rising obesity levels are significantly increasing the risk of Type 2 diabetes, cardiovascular diseases, and metabolic disorders, thereby driving the demand for continuous glucose monitoring systems, insulin delivery devices, and other advanced diabetes management technologies during the forecast period.

The presence of a substantial elderly population, affordable healthcare options, cost-effective labor, and less rigorous regulatory frameworks are driving diabetic device manufacturers to expand. They are prioritizing exploiting opportunities in emerging markets to increase their market dominance. The demand for diabetes devices is also rising due to technological advancements, including introducing of advanced insulin pumps and pens. Significant companies are concentrating on technological advancements and creating advanced products to secure a significant portion of the market. For instance, in April 2025, Medtronic announced the U.S. FDA submission for its interoperable MiniMed 780G insulin pump designed for integration with Abbott’s advanced CGM platform. The development is expected to accelerate the adoption of connected diabetes management ecosystems by improving interoperability, enhancing glucose control automation, and expanding access to advanced insulin delivery technologies across global markets.

Market Concentration & Characteristics

The diabetes devices market is moderately concentrated, with leading companies such as Medtronic plc, Abbott Laboratories, F.Hoffmann-La-Ltd., Bayer AG, and Lifescan, Inc. holding significant shares of the market. These companies offer advanced diabetes management technologies, including continuous glucose monitoring (CGM) systems, insulin pumps, smart insulin pens, blood glucose monitoring devices, and automated insulin delivery systems, enabling improved glycemic control, enhanced patient convenience, and better disease management outcomes. The market is continuously evolving due to technological advancements in sensor accuracy, wireless connectivity, AI-enabled diabetes management platforms, and integration with smartphones and wearable devices. In addition, the rising prevalence of diabetes, increasing awareness regarding early glucose monitoring, growing adoption of minimally invasive and home-based diabetes care solutions, and supportive government initiatives for chronic disease management are driving market growth and encouraging new entrants to introduce innovative and patient-centric diabetes device solutions.

The diabetes devices market is experiencing significant innovations and technological advancements, such as AI-enabled continuous glucose monitoring (CGM) systems, automated insulin delivery platforms, smart insulin pens, and connected diabetes management applications that enhance glucose control, patient convenience, and real-time disease monitoring. These technologies improve treatment accuracy, reduce the risk of hypoglycemia, and support personalized diabetes care, particularly for patients requiring continuous monitoring and remote healthcare support. For instance, in August 2024, Abbott Laboratories received U.S. FDA clearance for its over-the-counter Libre Rio continuous glucose monitoring system designed for people with Type 2 diabetes not using insulin, expanding accessibility to consumer-friendly glucose monitoring solutions. Furthermore, growing integration of smartphones, cloud-based analytics, and wearable technologies into diabetes care devices is accelerating innovation across the market. These factors are expected to drive the growth of the diabetes treatment devices market over the forecast period.

Partnerships and collaborations are playing a crucial role in shaping the growth trajectory of the diabetes devices market, as companies increasingly focus on integrating continuous glucose monitoring (CGM), insulin delivery systems, digital health platforms, and AI-based diabetes management technologies. For instance, in August 2024, Abbott Laboratories entered a global partnership with Medtronic to integrate Abbott’s FreeStyle Libre continuous glucose monitoring technology with Medtronic’s automated insulin delivery (AID) systems and smart insulin pens. The collaboration aims to create a more connected diabetes ecosystem capable of automatically adjusting insulin delivery based on real-time glucose readings. These collaborations are also helping companies strengthen their product portfolios, improve remote patient monitoring capabilities, and enhance personalized diabetes management, thereby driving competitive differentiation within the market.

Regulatory frameworks play a significant role in shaping the growth and commercialization of the diabetes devices market, as stringent approval standards and evolving compliance requirements directly influence product development, safety, interoperability, and market entry timelines. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly focusing on device accuracy, cybersecurity, software reliability, and real-time interoperability for continuous glucose monitoring (CGM) systems, insulin pumps, and automated insulin delivery devices. In March 2024, the U.S. FDA cleared the first over-the-counter continuous glucose monitor, Dexcom’s Stelo Glucose Biosensor System, for adults aged 18 years and older who do not use insulin. This landmark approval significantly broadened accessibility to CGM technology beyond traditional insulin-dependent patients and is expected to increase adoption of preventive glucose monitoring solutions globally.

Product substitutes remain an important factor influencing the diabetes devices market, as patients and healthcare providers continue to evaluate alternative diabetes management approaches that may reduce dependence on conventional monitoring and insulin delivery devices. Traditional self-monitoring blood glucose (SMBG) systems using fingerstick testing, oral antidiabetic medications, lifestyle modification programs, and emerging non-device-based diabetes therapies continue to act as substitutes for advanced diabetes devices such as continuous glucose monitoring (CGM) systems and insulin pumps. In many developing and price-sensitive markets, patients still prefer low-cost glucometers and oral therapies over technologically advanced wearable devices due to affordability concerns, limited reimbursement coverage, and a lack of awareness regarding connected diabetes care technologies.

Regional expansion strategies are playing a critical role in the growth of the diabetes devices market, as leading manufacturers increasingly focus on strengthening their presence in emerging economies and high-growth regions such as Asia-Pacific, Latin America, the Middle East, and parts of Europe. For instance, in January 2024, Medtronic received CE Mark approval in Europe for its MiniMed 780G system integrated with the Simplera Sync all-in-one disposable continuous glucose monitoring (CGM) sensor. The approval enabled the phased commercial launch of a more user-friendly automated insulin delivery system featuring simplified insertion, no fingersticks, and enhanced glucose management capabilities. This development is expected to accelerate the adoption of advanced diabetes management technologies across Europe by improving patient convenience, expanding accessibility to automated insulin delivery systems, and strengthening the regional shift toward connected and AI-enabled diabetes care solutions.

Type Insights

The BGM devices segment dominated the market in 2025 and accounted for the largest share of 57.8% of the overall revenue and is expected to witness the fastest CAGR of 12.4% over the forecast period. The growth is primarily driven by the increasing global prevalence of diabetes, rising demand for self-monitoring solutions, and growing adoption of home-based diabetes management technologies. In addition, the growing elderly population, increasing awareness regarding routine glucose monitoring, and expansion of remote patient monitoring programs are supporting the adoption of BGM devices across hospitals, clinics, and homecare settings. Technological advancements such as smartphone-connected glucose meters, automatic testing systems, and cloud-based data integration are further accelerating segment growth. For instance, in May 2024, Intuity Medical announced that its POGO Automatic blood glucose monitoring system became covered under Medicare Part B in the United States. The system is the first FDA-cleared automatic blood glucose monitor featuring integrated lancets and test cartridges for simplified one-step testing.

The insulin delivery devices segment is expected to witness a significant CAGR from 2026 to 2033. The growth is due to the rising global burden of diabetes and the growing need for convenient and effective insulin management solutions. Increasing adoption of insulin pens, pumps, and wearable delivery devices is enabling patients manage blood glucose levels more accurately and comfortably compared to traditional syringes. In addition, the growing elderly population, rising cases of obesity, and increasing prevalence of type 1 and type 2 diabetes are driving demand for advanced insulin delivery systems. Technological advancements such as smart insulin pens, connected pumps, and automated insulin delivery systems are also improving patient adherence and treatment outcomes. Furthermore, growing awareness about diabetes self-management, increasing healthcare spending, and better access to diabetes care devices across developing countries are further supporting market growth.

Distribution Channel Insights

The hospital pharmacies segment dominated the market and held the largest revenue share in 2025. Hospital pharmacies play a critical role in the distribution of insulin pumps, continuous glucose monitoring (CGM) systems, blood glucose monitoring devices, and diabetes consumables, particularly for newly diagnosed patients and individuals requiring intensive glycemic management. In addition, hospitals are increasingly adopting automated insulin delivery systems and networked glucose monitoring technologies to improve inpatient diabetes management and reduce complications associated with poor glycemic control. For instance, in October 2024, the Joint British Diabetes Societies for Inpatient Care and the Diabetes Technology Network issued updated guidelines supporting the use of wearable diabetes technologies, including CGM systems, insulin pumps, and hybrid closed-loop systems in hospitals. The guidelines encouraged hospitals to establish formal policies for inpatient diabetes technology adoption, highlighting the growing institutional acceptance of advanced diabetes devices in clinical settings.

The retail pharmacies segment is expected to witness the fastest CAGR over the forecast period. The growth is driven by the increasing demand for easy and quick access to diabetes care products. Retail pharmacies are becoming a preferred distribution channel for blood glucose monitors, insulin pens, test strips, continuous glucose monitoring devices, and other diabetes management products because they offer convenience, wide product availability, and immediate purchase options for patients. The growing number of diabetic patients requiring regular monitoring and continuous medication refills is also supporting segment growth. In addition, expanding pharmacy chains, rising awareness about diabetes self-care, and improved availability of advanced diabetes devices at retail stores are encouraging more consumers to purchase products through pharmacies. The increasing integration of retail pharmacies with online ordering, home delivery services, and insurance support programs is further driving demand across the diabetes devices market.

End-use Insights

The hospitals segment dominated the industry and held the largest revenue share in 2025. The growth is attributed to the increasing number of diabetes-related hospitalizations, rising prevalence of uncontrolled diabetes and associated complications, and growing adoption of advanced diabetes management technologies in inpatient care settings. Hospitals remain the primary end users of insulin pumps, continuous glucose monitoring (CGM) systems, automated insulin delivery devices, and blood glucose monitoring systems due to the availability of specialized endocrinology departments, trained healthcare professionals, and advanced patient monitoring infrastructure.

The segment’s growth is further supported by the increasing integration of connected diabetes technologies into hospital workflows to improve glycemic control, reduce complications, and enhance patient outcomes during hospitalization. In addition, hospitals are increasingly adopting automated insulin delivery systems and hybrid closed-loop technologies for inpatient diabetes management. For instance, a 2024 study published in Endocrine Practice by researchers from Mayo Clinic demonstrated that automated insulin delivery (AID) systems can be safely and effectively used in hospital settings, with patients using AID systems showing lower hyperglycemic events compared to conventional insulin management approaches.

The dignostic centers segmentis anticipated to grow at second fastest CAGR over the forecast period. The increasing demand for early diabetes detection and regular monitoring services are the factors contributing to the segments growth. Rising cases of diabetes and prediabetes are encouraging more people to undergo routine blood glucose and HbA1c testing at diagnostic centers. These centers are widely preferred as they provide accurate test results, advanced diagnostic technologies, and convenient testing services at affordable costs. In addition, growing health awareness, increasing preventive healthcare practices, and government initiatives promoting diabetes screening programs are driving patient visits to diagnostic facilities. The expansion of specialized diagnostic laboratories, improved access to testing services in urban and semi-urban areas, and rising adoption of advanced diabetes monitoring devices are also supporting segment growth across the diabetes devices market.

Regional Insights

North America diabetes devices market and accounted for the largest revenue share of 44.2% in 2025. The growth is driven by the high prevalence of diabetes, strong adoption of advanced diabetes management technologies, favorable reimbursement frameworks, and well-established healthcare infrastructure across the region. According to the Centers for Disease Control and Prevention (CDC), more than 38 million people in the U.S. are living with diabetes, while nearly 98 million adults are estimated to have prediabetes, creating substantial demand for glucose monitoring and insulin management devices. In addition, increasing obesity rates, sedentary lifestyles, and rising healthcare expenditure are further supporting the adoption of connected diabetes care technologies across the region.

U.S. Diabetes Devices Market Trends

Diabetes devices market in the U.S. is experiencing steady growth, driven by the rising prevalence of diabetes and obesity, increasing adoption of advanced glucose monitoring technologies, and growing demand for home-based and connected diabetes care solutions. The market is further supported by strong healthcare infrastructure, favorable reimbursement policies, high awareness regarding diabetes management, and rapid technological advancements in AI-enabled and smartphone-integrated diabetes devices. In addition, the increasing preference for minimally invasive and real-time glucose monitoring solutions among both Type 1 and Type 2 diabetic patients is accelerating product adoption across the country.

Europe Diabetes Devices Market Trends

Diabetes devices market in Europe is being reshaped by expanding use of automated insulin delivery technologies, favorable reimbursement policies, and growing government focus on digital healthcare integration. Rising diabetes prevalence, aging populations, and increasing awareness regarding early glucose monitoring are significantly driving demand for advanced diabetes management solutions across countries such as Germany, the UK, France, Italy, and Spain. In addition, Europe’s strong regulatory framework under the European Union Medical Device Regulation (EU MDR) is encouraging manufacturers to develop safer, interoperable, and technologically advanced diabetes devices, including AI-enabled insulin pumps, connected glucose monitoring systems, and smartphone-integrated diabetes management platforms and driving the growth of Europe diabetes care devices market.

The UK diabetes devices market is steadily growing. The growth attributed to the rising prevalence of diabetes, increasing adoption of continuous glucose monitoring (CGM) systems, expanding use of insulin pumps, and strong support from the National Health Service (NHS) for advanced diabetes management technologies. According to Diabetes UK, more than 5.8 million people in the UK are living with diabetes or prediabetes, creating significant demand for blood glucose monitoring devices, insulin delivery systems, and connected diabetes care solutions. The market is further driven by increasing awareness regarding early glucose monitoring, growing obesity rates, and the government’s focus on improving chronic disease management through digital healthcare initiatives. In addition, NHS reimbursement support for CGM technologies and hybrid closed-loop insulin delivery systems has significantly accelerated adoption among Type 1 diabetes patients across the country.

Diabetes devices market in Germany is experiencing significant growth in global diabetes devices market. The growth is driven by the strong healthcare infrastructure, increasing adoption of advanced glucose monitoring technologies, and favorable reimbursement policies for diabetes care devices. Germany has one of the largest diabetic populations in Europe, creating substantial demand for continuous glucose monitoring (CGM) systems, insulin pumps, blood glucose monitoring devices, and automated insulin delivery technologies. The market is further supported by increasing awareness regarding preventive diabetes management, growing elderly population, and rising government focus on digital healthcare integration.

Asia Pacific Diabetes Devices Market Trends

The growth of the Asia-Pacific diabetes devices market is primarily driven by rapidly increasing prevalence of diabetes, expanding healthcare infrastructure, rising healthcare expenditure, and growing awareness regarding early glucose monitoring and diabetes management. Countries such as China, India, Japan, and South Korea are witnessing substantial growth in diabetic populations driven by urbanization, sedentary lifestyles, unhealthy dietary habits, and rising obesity rates, thereby increasing demand for blood glucose monitoring systems, continuous glucose monitoring (CGM) devices, insulin pumps, and smart insulin delivery technologies. According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, the Western Pacific region accounts for one of the largest shares of the global diabetic population, creating strong growth opportunities for diabetes device manufacturers across Asia-Pacific.

Diabetes devices market in China is growing due to the country’s rapidly increasing diabetic population, expanding healthcare infrastructure, rising healthcare expenditure, and growing adoption of advanced diabetes management technologies. China has one of the largest diabetic populations globally, creating substantial demand for blood glucose monitoring devices, continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin delivery solutions. According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, China accounts for a significant share of the global diabetes burden, driven by urbanization, aging demographics, sedentary lifestyles, and increasing obesity rates. The market is further supported by rising awareness regarding preventive healthcare, increasing penetration of digital health platforms, and strong government initiatives aimed at improving chronic disease management and expanding access to medical technologies. In addition, the growing popularity of home-based diabetes monitoring and smartphone-connected glucose management systems is accelerating adoption of connected diabetes devices across urban and semi-urban areas.

The South Korea diabetes devices market is largely driven by the increasing adoption of digital healthcare technologies, and strong government support for advanced chronic disease management solutions. The country has witnessed a significant increase in Type 2 diabetes cases due to sedentary lifestyles, dietary changes, and rising obesity rates, thereby increasing demand for blood glucose monitoring devices, continuous glucose monitoring (CGM) systems, insulin pumps, and connected diabetes care platforms. South Korea’s highly developed healthcare infrastructure and widespread digital connectivity have accelerated the adoption of smartphone-integrated glucose monitoring systems, AI-enabled diabetes management applications, and remote patient monitoring technologies.

Latin America Diabetes Devices Market Trends

The Latin America diabetes devices is an emerging market and is expected to grow at the significant rate due to various factors. Increasing urbanization, sedentary lifestyles, unhealthy dietary habits, and rising obesity rates are contributing to the growing diabetic population across emerging economies, thereby creating substantial demand for blood glucose monitoring devices, continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin delivery technologies. In addition, improving access to healthcare services, expansion of private healthcare facilities, and increasing government initiatives focused on chronic disease management are supporting the adoption of advanced diabetes care solutions across the region. The market is also benefiting from the growing penetration of digital health platforms, telemedicine services, and remote patient monitoring technologies, which are improving accessibility to diabetes management in underserved and rural areas.

Diabetes devices market in Brazil is growing and is supported by the rising prevalence of diabetes, increasing obesity rates, improving healthcare access, and growing adoption of advanced diabetes management technologies across the country. Brazil represents one of the largest healthcare markets in Latin America, with a substantial diabetic population driving demand for blood glucose monitoring devices, continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin delivery technologies. The market is further supported by increasing public awareness regarding diabetes prevention and management, expansion of private healthcare facilities, and government initiatives aimed at improving chronic disease care.

Middle East & Africa Diabetes Devices Market Trends

The Middle East and Africa (MEA) diabetes devices market is growing steadily, owing to the rising prevalence of diabetes, increasing obesity rates, improving healthcare infrastructure, and growing awareness regarding early diagnosis and diabetes management across the region. Rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and genetic predisposition to diabetes are significantly contributing to the increasing burden of Type 2 diabetes in countries such as Saudi Arabia, the UAE, South Africa, and Egypt. According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, the Middle East and North Africa region continues to report one of the highest diabetes prevalence rates globally, creating strong demand for blood glucose monitoring systems, continuous glucose monitoring (CGM) devices, insulin pumps, and smart insulin delivery technologies.

The diabetes devices market in Saudi Arabia is experiencing notable growth. Saudi Arabia has one of the highest diabetes prevalence rates in the Middle East, primarily driven by sedentary lifestyles, unhealthy dietary patterns, and increasing rates of overweight and obesity among adults. This has significantly increased demand for blood glucose monitoring devices, continuous glucose monitoring (CGM) systems, insulin pumps, and connected diabetes management technologies across hospitals, clinics, and homecare settings. The market is further benefiting from the Saudi government’s Vision 2030 healthcare modernization strategy, which emphasizes healthcare digitization, preventive care, telemedicine expansion, and improved access to advanced medical technologies.

Key Diabetes Device Company Insights

The diabetes devices market is highly competitive and has several key players. The major market players are focusing on expanding their geographical presence, forming partnerships to improve patient mobility and care through advanced diabetes devices technologies, leveraging strategic collaborations, and exploring mergers and acquisitions.

Recent Development

• In September 2025, Medtronic received U.S. FDA clearance for integration of the MiniMed 780G insulin pump with Abbott’s Instinct CGM sensor and also secured approval for use in adults with insulin-requiring Type 2 diabetes. The approval significantly expanded the company’s automated insulin delivery portfolio and strengthened the partnership between Medtronic and Abbott.

• In September 2024, Senseonics Holdings and Ascensia Diabetes Care received U.S. FDA clearance for the Eversense 365 CGM system, the world’s first implantable continuous glucose monitor with a one-year sensor life. The approval marked a significant advancement in long-term glucose monitoring technologies and strengthened innovation within the CGM segment.

• In June 2024, Insulet Corporation announced the full commercial launch of Omnipod 5 with expanded sensor integrations in the UK and the Netherlands. The automated insulin delivery system became compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus sensors, improving flexibility and patient access to integrated diabetes management technologies.

• In July 2023, CharmHealth and Bioverge have jointly invested in My Diabetes Tutor, a startup dedicated to improving the lives of individuals with diabetes.

Diabetes Devices Market Report Scope

Global Diabetes Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the global diabetes devices market report based on type, distribution channel, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • BGM Devices

    • Self-Monitoring Devices

      • Blood Glucose Meters

      • Testing Strips

      • Lancets

    • Continuous Glucose Monitoring Devices

      • Sensors

      • Transmitters

      • Receiver

  • Insulin Delivery Devices

    • Pens

    • Pum

    • Syringes

    • Jet Injectors

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital pharmacies

  • Retail Pharmacies

  • Diabetes Clinics/Centers

  • Online Pharmacies

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Diagnostic Centers

  • Homecare

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Thailand

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait